Paper42201625
Gut microbiota and cancer immunotherapy: from dysbiosis to personalized immune checkpoint blockade optimization.
Akram F and 3 others. Folia Microbiol (Praha), 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Gut microbiota and cancer immunotherapy: from dysbiosis to personalized immune checkpoint blockade optimization. Papers, record 42201625. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42201625
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Gut microbiota and cancer immunotherapy: from dysbiosis to personalized immune checkpoint blockade optimization.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References200
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38319892 | Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. | NEJM Evid | 2022 | https://conductscience.org/library/papers/38319892 | PubMed |
| 2 | 28291584 | Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. | Lancet Oncol | 2017 | https://conductscience.org/library/papers/28291584 | PubMed |
| 3 | 32499569 | Host dysbiosis negatively impacts IL-9-producing T-cell differentiation and antitumour immunity. | Br J Cancer | 2020 | https://conductscience.org/library/papers/32499569 | PubMed |
| 4 | 28878676 | PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. | Front Pharmacol | 2017 | https://conductscience.org/library/papers/28878676 | PubMed |
| 5 | 33264544 | Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. | N Engl J Med | 2020 | https://conductscience.org/library/papers/33264544 | PubMed |
| 6 | 34239137 | Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. | Nat Med | 2021 | https://conductscience.org/library/papers/34239137 | PubMed |
| 7 | 37530622 | Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study. | Blood Adv | 2023 | https://conductscience.org/library/papers/37530622 | PubMed |
| 8 | 28885881 | Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28885881 | PubMed |
| 9 | 36460017 | Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. | Lancet Oncol | 2023 | https://conductscience.org/library/papers/36460017 | PubMed |
| 10 | 37361202 | The gut dysbiosis-cancer axis: illuminating novel insights and implications for clinical practice. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37361202 | PubMed |
| 11 | 33485464 | First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. | Lancet | 2021 | https://conductscience.org/library/papers/33485464 | PubMed |
| 12 | 15790844 | Host-bacterial mutualism in the human intestine. | Science | 2005 | https://conductscience.org/library/papers/15790844 | PubMed |
| 13 | 35291651 | Commensal Microbiota and Cancer Immunotherapy: Harnessing Commensal Bacteria for Cancer Therapy. | Immune Netw | 2022 | https://conductscience.org/library/papers/35291651 | PubMed |
| 14 | 32264958 | Tumor microenvironment complexity and therapeutic implications at a glance. | Cell Commun Signal | 2020 | https://conductscience.org/library/papers/32264958 | PubMed |
| 15 | 34077643 | Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. | N Engl J Med | 2021 | https://conductscience.org/library/papers/34077643 | PubMed |
| 16 | 29132146 | Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. | Nature | 2017 | https://conductscience.org/library/papers/29132146 | PubMed |
| 17 | 28634130 | The inhibitory impacts of Lactobacillus rhamnosus GG-derived extracellular vesicles on the growth of hepatic cancer cells. | Microb Pathog | 2017 | https://conductscience.org/library/papers/28634130 | PubMed |
| 18 | 23778791 | Compartmentalized and systemic control of tissue immunity by commensals. | Nat Immunol | 2013 | https://conductscience.org/library/papers/23778791 | PubMed |
| 19 | 37028428 | Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. | Cell | 2023 | https://conductscience.org/library/papers/37028428 | PubMed |
| 20 | 37555952 | Microbiota as the unifying factor behind the hallmarks of cancer. | J Cancer Res Clin Oncol | 2023 | https://conductscience.org/library/papers/37555952 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42201625
GET https://conductscience.org/api/papers/v1/42201625/references?page=2